- Research article
- Open Access
- Open Peer Review
Null mutation for Macrophage Migration Inhibitory Factor (MIF) is associated with less aggressive bladder cancer in mice
BMC Cancer volume 7, Article number: 135 (2007)
Inflammatory cytokines may promote tumorigenesis. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine with regulatory properties over tumor suppressor proteins involved in bladder cancer. We studied the development of bladder cancer in wild type (WT) and MIF knockout (KO) mice given N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN), a known carcinogen, to determine the role of MIF in bladder cancer initiation and progression.
5-month old male C57Bl/6 MIF WT and KO mice were treated with and without BBN. Animals were sacrificed at intervals up to 23 weeks of treatment. Bladder tumor stage and grade were evaluated by H&E. Immunohistochemical (IHC) analysis was performed for MIF and platelet/endothelial cell adhesion molecule 1 (PECAM-1), a measure of vascularization. MIF mRNA was analyzed by quantitative real-time polymerase chain reaction.
Poorly differentiated carcinoma developed in all BBN treated mice by week 20. MIF WT animals developed T2 disease, while KO animals developed only T1 disease. MIF IHC revealed predominantly urothelial cytoplasmic staining in the WT control animals and a shift toward nuclear staining in WT BBN treated animals. MIF mRNA levels were 3-fold higher in BBN treated animals relative to controls when invasive cancer was present. PECAM-1 staining revealed significantly more stromal vessels in the tumors in WT animals when compared to KOs.
Muscle invasive bladder cancer with increased stromal vascularity was associated with increased MIF mRNA levels and nuclear redistribution. Consistently lower stage tumors were seen in MIF KO compared to WT mice. These data suggest that MIF may play a role in the progression to invasive bladder cancer.
Bladder cancer is a common urinary tract malignancy. In 2007 there will be an estimated 67,160 new cases with 13,750 deaths in the United States alone . Stage at diagnosis is fundamental to outcome as 50% of patients with muscle invasion have metastatic disease. Current therapies for advanced disease are disappointing. Even with aggressive surgical and medical treatment most patients with advanced bladder cancer ultimately succumb to their disease.
Recent research has suggested an important role for inflammatory cytokines and chemokines in the development of cancer. They may promote tumorigenesis by providing an environment that enhances cell proliferation, survival and migration. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that has regulatory properties over mediators such as p53 and the retinoblastoma protein (pRb) known to be involved in invasive bladder cancer [2, 3]. Overexpression of MIF has been implicated in several cancers [4–6]. We studied the effects of knocking out the gene for MIF (mif-/-) on the development of bladder cancer in mice given N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN).
Mice lacking MIF (MIF-KO) were generated by homologous recombination and backcrossed into a pure C57BL/6 background (generation N8) . Animals were bred and maintained at the University of Connecticut Health Center for Laboratory Animal Care under National Institutes of Health guidelines. All procedures were approved by an institutional animal care committee. Fifty 5 month old C57Bl/6 MIF-KO and WT mice were housed in a controlled environment with a 12 hour light – 12 hour dark cycle and provided food and water ad libitum. The experimental group received BBN (TCI America, Portland, OR) 0.05% in water in brown bottles throughout. Two mice from each group (WT control and treated, KO control and treated) were euthanized by CO2 inhalation at 4, 8, 12, 16, 20 and 23 weeks. Bladders were harvested and inspected for tumor prevalence. Half of each bladder, and tumor if present, was used for pathologic evaluation and half for analysis of mRNA.
Bladder halves were placed in PBS/formaldehyde for 24 hours and then transferred to PBS. Bladder halves were sagitally sectioned into 3 levels (inner, mid, outer) and stained with H&E. Characteristics such as number of cell layers, nuclear size, nuclear membrane irregularity, chromatin pattern, nuclear:cytoplasmic ratio, presence of nucleoli and mitosis were evaluated in order to provide a final diagnosis of (1) normal, (2) metaplasia, (3) atypia, (4) carcinoma in situ (CIS) and (5) carcinoma. The term carcinoma is applied to all cancers as lesions showed mixed histology with both transitional and squamous elements. Tumor stage and grade are the most predictive variables with regard to prognosis and these were the main outcome metrics in our model. Invasion was diagnosed if tumor cells were seen infiltrating the muscle layers of the bladder. A single pathologist (P.H.) reviewed all slides in a blinded fashion.
IHC for MIF was performed in a standard method. Endogenous peroxidase activity was blocked by treatment with 3% H2O2 in PBS for 30 min. Non-specific staining was blocked by incubation with Power Block™ Universal Blocking agent (Biogenex, San Ramon, CA). Specimens were rinsed in PBS. Tissue sections were stained with a rabbit polyclonal anti-MIF antibody (Cell Sciences, CPM300). Sections were incubated overnight at 4–8°C (dilution 1:1000). Bound antibody was detected with a secondary biotinylated anti-rabbit antibody for 30 min at room temperature (1:200) and visualized using diaminobenzidine (DAB) as a chromogenic substrate according to the manufacturer's instructions (Vector Labs, Burlingame, CA).
Sections were evaluated for degree of nuclear staining and scored from 0–3 corresponding to negative, weak, intermediate and strong staining respectively. Results were quantified using an H-score as previously described . Three fields were chosen representing areas of maximal staining at 200× magnification. The total number of nuclei and total number staining at each intensity were counted. The average percentage positive for each group was calculated. H-score was calculated as equal to (% of cells stained at intensity 0 × 0) + (% of cells stained at intensity 1 × 1) + (% of cells stained at intensity 2 × 2) + (% of cells stained at intensity 3 × 3). This resulted in a score between 0 and 300 where 300 is equal to 100% of tumor cell nuclei staining strongly.
IHC for PECAM-1 was performed in a standard method. Endogenous peroxidase activity was blocked by treatment with 3% H2O2 for 10 min. Non-specific staining was blocked by incubation with Power Block™ for 10 min. Tissue sections were stained with a goat polyclonal anti-PECAM antibody (Santa Cruz Biotechnology, M20 SC-1506) at 1:500 dilution in PBS-BSA overnight at 4°C. Bound anti-PECAM-1 antibody was detected with a secondary biotinylated horse-anti-goat antibody for 30 min at room temperature (1:200) and visualized using DAB.
Microvessel density (MVD) was calculated by the Weidner method . Using light microscopy (200× field), tumors were evaluated for associated angiogenesis. The region in each specimen that represented the area of maximal activity was then processed to capture the vascular structures present with minimal background using Image Pro Plus analytical software (Media Cybernetics, Silver Spring, MD). Results were quantified and defined in terms of pixels/field.
Quantitative polymerase chain reaction for mRNA
Quantitative real time PCR (qPCR) was performed for MIF and TNF-α mRNA with GAPDH as an internal control. Total RNA was extracted from bladder tissues with TRIzol® Reagent (Invitrogen Life Technologies, Carlsbad, CA) following the manufacturer's protocol. Total RNA was converted to cDNA by ABI High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA) following the manufacturer's protocol. qPCR was performed for different gene expression in separate wells (singleplex assay) of a 96-well plate in a reaction volume of 20 μl. Three replicates of each sample were amplified using Assays-on-Demand Gene Expression assay (Assay # Mm01604696_g1 for MIF, Mm00443258_m1 for TNF and Mm99999915_g1 for GAPDH) which contain predesigned, unlabeled gene-specific PCR primers and TaqMan MGB FAM dye-labeled probe. The PCR reaction mixture (including 2 × TaqMan Universal PCR Master Mix, 20 × Assays-on-Demand Gene Expression Assay Mix, 50 ng of cDNA) was run in Applied Biosystems ABI Prism 7300 Sequence Detection System instrument utilizing universal thermal cycling parameters. For genes for which the efficiencies of target and endogenous control amplification were approximately equal, the relative quantification expression in a test sample to a reference calibrator sample (ΔΔCt Method) was used for data analysis. For genes which were not amplified with the same efficiency as the endogenous control, The Relative Standard Curve method in which target quantity is determined from the standard curve and divided by the target quantity of the calibrator was used.
All BBN treatment groups displayed equal evidence of sub-mucosal inflammation and edema from the earliest time point. Varying degrees of atypia and metaplasia were noted through week 12 (Figure 1). Carcinoma, representing focal areas of CIS, was noted at 16 weeks in both WT and KO mice. At 20 and 23 weeks specimens showed poorly differentiated, high-grade, carcinoma in both genotypes (Figure 1). Tumors were bulky, occupying the majority of bladder lumens precluding precise assessment of the number of tumors present per bladder. However, stage and grade are the most important variables with regard to prognosis in bladder cancer. Although no difference in grade was noted, BBN treated MIF KO bladders (n = 3) had consistently lower tumor stage with no invasion into muscle layers noted (T1). Muscle invasion (T2) was present in all MIF WT bladders (n = 5) at 20–23 wks representing a 100% discordance in phenotype. One MIF KO mouse died prior to sacrifice at 22 weeks with cancer noted but was excluded from analysis because necrolysis prevented accurate tumor staging.
At early time points (4–16 wks) MIF was noted to be constitutively expressed and localized to the urothelial layer in the WT groups, which is in agreement with a prior report . No staining was seen in the KO mice. Staining intensity revealed no pathologic difference between groups treated with and without BBN including areas of metaplasia and CIS. No change in cellular localization was seen either. At 20 weeks when cancer was present, increased intensity of MIF staining was noted in WT treated specimens relative to earlier specimens and to WT untreated specimens. WT control animals showed predominantly cytoplasmic staining with scant nuclear staining confined to the urothelial layer. BBN treated animals showed intense cytoplasmic and nuclear staining in a large proportion of tumor cells (Figure 2). Mean nuclear H-scores for WT control and BBN-treated animals were 63.3 and 152 respectively (p = 0.2, based on the Wilcoxon rank sum test of location difference).
PECAM-1 staining showed an increase in the number of tumor associated vessels in the WT as compared to KO animals (Figure 3). Mean MVD ± SE for the WT and KO specimens were 11.7 × 106 ± 1.7 × 106 and 6.7 × 106 ± 1.0 × 106 respectively (p = 0.04, based on the two sample t-test for difference in means).
MIF mRNA levels were evaluated in bladders from WT animals. The KO bladders had no evidence of MIF mRNA expression by RT-PCR or protein by IHC. MIF mRNA levels gradually increased in the treated animals versus controls (Figure 4). By week 23 when invasive cancer was present, the observed MIF mRNA level was 3-fold higher in the BBN treated mice compared to controls. TNFα, a marker of inflammation, was elevated equally in WT and KO treated animals from the earliest time points.
To investigate the statistical significance of the treatment effect we fit a linear regression model to the data. Residual diagnostics for non-constant variance and non-normality revealed no evidence of model inadequacy. We tested for an overall treatment effect by performing a partial F-test with p < .01, indicating a highly statistically significant overall treatment effect.
MIF is a widely expressed molecule first described for its ability to inhibit the random migration of macrophages in vitro . Its participation in the host response to inflammation and defense is well established . As a result of its biological actions, MIF may prove to play an important role in tumorigenesis. MIF activates the MAPK/ERK signaling pathway, which regulates cellular proliferation and survival. MIF has been reported to inhibit p53 tumor suppressor activity via a COX-2/PGE2 dependant pathway resulting in cell growth and preventing cell regulated apoptosis [2, 13]. It has also been reported to increase cyclin D transcription leading to increased phosphorylation of pRb resulting in cellular proliferation [3, 14]. In addition, MIF has recently been shown to promote survival in fibroblasts via a phosphoinositide-3-kinase (PI3K)/Akt signaling pathway . Recent publications have suggested that MIF expression can lead to increased angiogenesis which is integral to cancer growth, invasion and metastasis [16, 17].
MIF has been implicated in prostate, lung and breast cancer with overexpression shown to correlate with tumor grade/stage and prognosis [4–6]. Bladder epithelial cells not only produce MIF but may also display upregulation in response to diverse stimuli [10, 18]. Recently, inhibition of MIF with hyaluronic acid, anti-MIF antibody or MIF anti-sense, was shown to decrease in vitro bladder cancer cell proliferation and cytokine expression .
Our results suggest that MIF may be involved in the progression of bladder cancer to muscle invasion. The absence of MIF did not impair tumor development but was associated with the absence of tumor invasion into muscle. Muscle invasive disease was present in all WT animals and was associated with a notable increase in stromal angiogenesis. At the time of muscle invasion MIF mRNA levels were three-fold higher in the treated versus control animals. In addition, a pattern of MIF protein nuclear redistribution was noted. mRNA levels for TNFα, another inflammatory mediator, were elevated equally in both the WT and KO mice throughout the duration of the study and pathologic evidence of inflammation (sub-mucosal edema, inflammatory cell infiltrate) was equal as well, suggesting no difference in exposure to metabolites of BBN.
The mechanism by which MIF may facilitate invasion of tumor cells is currently unknown. Cell lines have shown an increased expression of matrix metalloproteases, important in the breakdown of the extracellular matrix, when exposed to recombinant MIF [19, 20]. Cancer cells have demonstrated an increase in invasive capacity when exposed to recombinant MIF  or co-cultured with macrophages leading to a TNF-α dependant increase in MIF expression via an NFκ-B pathway . Additionally, we have recently reported both in vitro and in vivo evidence that MIF promotes bladder muscle cell death which could facilitate tumor cell invasion .
Angiogenesis is recognized as an important step in tumor invasion and metastasis. Proangiogenic factors have been identified in bladder cancer and MVD has been shown to be a prognostic indicator . Many of the same studies noted above also evaluated angiogenesis and were able to show increased angiogenic properties related to the expression of MIF. Ovarian and breast cancer cells had a MIF-dependent increase in angiogenic factors when co-cultured with macrophages . In vivo studies utilizing small interfering RNA (siRNA) transfected cells and inoculation of nude mice showed tumors with less associated angiogenesis and invasive capacity . Our study compliments these findings in an in vivo model by showing a statistically significant increase in tumor associated vascular structures in MIF WT compared to KO mice.
Translocation of protein from the cytoplasm to the nucleus is seen in many regulatory molecules. Proteins reported to do so in cancer may interact with transcription factors important for cell growth, angiogenesis and invasion. Nuclear redistribution of MIF has been seen in tumor tissues from lung adenocarcinoma patients and glioblastoma multiforme tissue [23, 24]. Although MIF was seen in normal lung tissue by IHC, staining was noted only in the cytoplasm. As in our study, MIF was seen only in the cytoplasm in normal lung tissue by IHC. In lung cancer specimens MIF staining was noted to be more intense and seen in the nuclei of a large portion of the specimens. Stratification of patient outcome was possible based on the presence of nuclear staining. However, contrary to our findings in mice, nuclear staining portended a better clinical outcome for lung cancer patients . In normal brain tissue no cytoplasmic or nuclear staining was noted for MIF yet brain cancer specimens revealed nuclear localization of MIF. We have preliminary data from human bladder cancer specimens showing similar redistribution of MIF to the nucleus when compared to benign tissue (Figure 2).
This is the first report of the impact of MIF gene deletion on the development and progression of bladder cancer. Our findings are derived from a small pilot study and will need to be confirmed and expanded in larger studies that identify the mechanisms of MIF involvement in the progression to muscle invasion.
MIF KO mice developed consistently lower stage tumors with less associated angiogenesis in a BBN model of bladder cancer. Tumor presence was associated with nuclear redistribution of MIF. These preliminary data suggest that MIF plays a role in the progression to muscle invasive disease.
Macrophage Migration Inhibitory Factor
Platelet Endothelial Cell Adhesion Molecule
Cancer Facts and Figures. 2007, , American Cancer Society
Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, Moll U, Muller W, Bucala R: The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A. 2003, 100: 9354-9359. 10.1073/pnas.1533295100.
Petrenko O, Moll UM: Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell. 2005, 17: 225-236. 10.1016/j.molcel.2004.11.052.
Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K: Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res. 2002, 8: 3755-3760.
Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M, Toi M: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res. 2002, 93: 389-396.
Meyer-Siegler K, Hudson PB: Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology. 1996, 48: 448-452. 10.1016/S0090-4295(96)00207-5.
Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999, 189: 341-346. 10.1084/jem.189.2.341.
Detre S, Saclani Jotti G, Dowsett M: A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995, 48: 876-878. 10.1136/jcp.48.9.876.
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991, 324: 1-8.
Meyer-Siegler KL, Leifheit EC, Vera PL: Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer. 2004, 4: 34-10.1186/1471-2407-4-34.
David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A. 1966, 56: 72-77. 10.1073/pnas.56.1.72.
Calandra T, Bucala R: Macrophage migration inhibitory factor (MIF): a glucocorticoid counter-regulator within the immune system. Crit Rev Immunol. 1997, 17: 77-88.
Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999, 190: 1375-1382. 10.1084/jem.190.10.1375.
Petrenko O, Fingerle-Rowson G, Peng T, Mitchell RA, Metz CN: Macrophage migration inhibitory factor deficiency is associated with altered cell growth and reduced susceptibility to Ras-mediated transformation. J Biol Chem. 2003, 278: 11078-11085. 10.1074/jbc.M211985200.
Lue H, Thiele M, Franz J, Dahl E, Speckgens S, Leng L, Fingerle-Rowson G, Bucala R, Luscher B, Bernhagen J: Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene. 2007
Ren Y, Chan HM, Fan J, Xie Y, Chen YX, Li W, Jiang GP, Liu Q, Meinhardt A, Tam PK: Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene. 2006, 25 (25): 3501-3508. 10.1038/sj.onc.1209395.
Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappaB and JNK. J Immunol. 2005, 175: 1197-1205.
Meyer-Siegler KL, Vera PL: Substance P induced release of macrophage migration inhibitory factor from rat bladder epithelium. J Urol. 2004, 171: 1698-1703. 10.1097/01.ju.0000115883.49365.1a.
Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S, Minami A: Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J Biol Chem. 2002, 277: 7865-7874. 10.1074/jbc.M106020200.
Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J: Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem. 2000, 275: 444-450. 10.1074/jbc.275.1.444.
Taylor JA, Zhu Q, Irwin B, Maghaydah Y, Tsimikas J, Pilbeam C, Leng L, Bucala R, Kuchel GA: Null mutation in macrophage migration inhibitory factor prevents muscle cell loss and fibrosis in partial bladder outlet obstruction. Am J Physiol Renal Physiol. 2006, 291: F1343-53. 10.1152/ajprenal.00144.2006.
Charlesworth PJ, Harris AL: Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol. 2006, 3: 157-169. 10.1038/ncpuro0434.
Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 2000, 89: 334-341. 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N.
Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapston TB, Benos DJ: Differential gene expression profiling in human brain tumors. Physiol Genomics. 2001, 5: 21-33.
The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/7/135/prepub
HERA Foundation Funds (JAT)
John Hartford Foundation & American Geriatrics Society, Dennis W. Jahnigen Career Development Scholars Award (JAT)
The Patrick & Catherine Weldon Donaghue Medical Research Foundation (GK)
NIH RO1DK48361 (CP), R01AR050498 and AR049610 (RB)
The author(s) declare that they have no competing interests.
JAT and CP designed the study, and along with GK, coordinated all aspects of the study and drafted the manuscript. OSV was involved in RNA extraction, quantitative PCR and interpretation of data. PH and KC provided pathologic analysis and interpretation of IHC. JT provided statistical analysis. RB and LL provided the founder mice for the MIF KO colony at UCHC and reviewed the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Taylor, J.A., Kuchel, G.A., Hegde, P. et al. Null mutation for Macrophage Migration Inhibitory Factor (MIF) is associated with less aggressive bladder cancer in mice. BMC Cancer 7, 135 (2007) doi:10.1186/1471-2407-7-135
- Bladder Cancer
- Migration Inhibitory Factor
- Invasive Bladder Cancer
- Muscle Invasion
- Migration Inhibitory Factor Expression